Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283343 | 0.90 | CRBN (0.54) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL328542 | 0.87 | CRBN (0.54) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL282990 | 0.86 | CRBN (0.56) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL287793 | 0.86 | CRBN (0.54) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL282617 | 0.85 | CRBN (0.56) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL24113869 | 0.85 | CRBN (0.58) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL283824 | 0.85 | CRBN (0.58) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL282665 | 0.85 | CRBN (0.59) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL282730 | 0.84 | CRBN (0.55) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL12638481 | 0.84 | CRBN (0.46) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | CRBN 1/4885DDB1 1337/4885TNF 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.